Company Analysis
Sign in

Biomea Fusion, Inc. (BMEA)

Nasdaq: BMEA · Pharmaceutical Preparations · San Carlos, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.1
◀ Past 4.7● Present 3.6▶ Future 6.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Biomea Fusion, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 4 in 2024 and 2 in 2023
Applications published
24
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Organic fine chemistry5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BIOMEA FUSION, INC. its own name
named as the applicant on its applications, in US
0 granted
24 published
BIOMEA FUSION, INC. its own name
US, as the owner printed on each patent
11 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 15, 202512,275,739Inhibitors of menin-MLL interactionPharmaceuticalsBIOMEA FUSION, INC.
Mar 18, 202512,251,385Covalent inhibitors of menin-MLL interaction for diabetes mellitusPharmaceuticalsBIOMEA FUSION, INC.
Feb 4, 202512,215,113Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]PharmaceuticalsBIOMEA FUSION, INC.
Oct 15, 202412,116,371Substituted pyridines as irreversible inhibitors of menin-MLL interactionOrganic fine chemistryBIOMEA FUSION, INC.
Sep 3, 202412,077,544Irreversible inhibitors of menin-MLL interactionOrganic fine chemistryBIOMEA FUSION, INC.
Jun 25, 202412,018,032Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interactionPharmaceuticalsBIOMEA FUSION, INC.
Apr 2, 202411,945,785Pyrazine compounds as inhibitors of FLT3Organic fine chemistryBIOMEA FUSION, INC.
Dec 19, 202311,845,753Inhibitors of menin-mll interactionPharmaceuticalsBIOMEA FUSION, INC.
Jul 18, 202311,702,421Substituted pyridines as irreversible inhibitors of menin-MLL interactionOrganic fine chemistryBIOMEA FUSION, INC.
Nov 16, 202111,174,263Inhibitors of menin-MLL interactionPharmaceuticalsBIOMEA FUSION, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0353854FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENINPharmaceuticalsBIOMEA FUSION, INC.
Oct 9, 20252025/0312335FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFORPharmaceuticalsBIOMEA FUSION, INC.
Oct 2, 20252025/0304572HETEROCYCLIC GLP-1R AGONISTSPharmaceuticalsBIOMEA FUSION, INC.
Jul 31, 20252025/0243207SYNTHETIC METHODS FOR PREPARING A PYRIDINECARBOXAMIDE COMPOUNDOrganic fine chemistryBIOMEA FUSION, INC.
May 22, 20252025/0161320COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUSPharmaceuticalsBIOMEA FUSION, INC.
May 1, 20252025/0136558PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3Organic fine chemistryBIOMEA FUSION, INC.
Feb 27, 20252025/0066386INHIBITORS OF KRASPharmaceuticalsBIOMEA FUSION, INC.
Dec 19, 20242024/0417404CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTIONPharmaceuticalsBIOMEA FUSION, INC.
Dec 12, 20242024/0409558IRREVERSIBLE INHIBITORS OF KRASPharmaceuticalsBIOMEA FUSION, INC.
Nov 14, 20242024/0376112N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOFOrganic fine chemistryBIOMEA FUSION, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 10 · Organic fine chemistry 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BMEA · research, not advice